Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn’s Disease Patients
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: Information regarding the efficacy of early infliximab treatment in pediatric patients with Crohn’s disease (CD) is limited. We aimed to evaluate the impact of early combined immunosuppression on linear growth in pediatric patients with CD by performing step-up comparisons. Methods: This retrospective study included pediatric patients with moderate-to-severe CD, who received a combination therapy with infliximab and azathioprine for at least 3 years and sustained corticosteroid-free remission without loss of response. The z-scores of the growth indicators obtained at the time of diagnosis and annually for 3 years thereafter were compared between the two groups. Results: The early combined immunosuppression group displayed significantly increased linear growth 3 years after diagnosis (p=0.026). A significant difference was also observed in the linear growth 3 years after diagnosis between subgroups of Tanner stages 1–2 (p=0.016). Conclusions: The early introduction of biologics should be considered to improve linear growth in pediatric patients with CD.
Abstract
Background/Aims: Information regarding the efficacy of early infliximab treatment in pediatric patients with Crohn’s disease (CD) is limited. We aimed to evaluate the impact of early combined immunosuppression on linear growth in pediatric patients with CD by performing step-up comparisons. Methods: This retrospective study included pediatric patients with moderate-to-severe CD, who received a combination therapy with infliximab and azathioprine for at least 3 years and sustained corticosteroid-free remission without loss of response. The z-scores of the growth indicators obtained at the time of diagnosis and annually for 3 years thereafter were compared between the two groups. Results: The early combined immunosuppression group displayed significantly increased linear growth 3 years after diagnosis (p=0.026). A significant difference was also observed in the linear growth 3 years after diagnosis between subgroups of Tanner stages 1–2 (p=0.016). Conclusions: The early introduction of biologics should be considered to improve linear growth in pediatric patients with CD.
참고문헌 (32)
- Ruemmele FM, "Consensus guidelines of ECCO", ESPGHAN on the medical management of pediatric Crohn's disease, 2014, pp.8, 1179~1207
- Caprilli R, "European evidence based consensus on the diagnosis and management of Crohn's disease: special situations", Gut, 55(Suppl 1), pp.i36~i58 (2006)[DOI]
- Hyams J, "Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children", Gastroenterology, 132, pp.863~873 (2007)[DOI]
- Hyams JS, "Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children", Gastroenterology, 143, pp.365~374 (2012)[DOI]
- D'Haens G, "Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomized trial", Lancet, 371, pp.660~667 (2008)[DOI]
- Khanna R, "Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial", Lancet, 386, pp.1825~1834 (2015)[DOI]
- Lee YM, "Infliximab Top-Down strategy is superior to Step-Up in maintaining long-term remission in the treatment of pediatric Crohn disease", J Pediatr Gastroenterol Nutr, 60, pp.737~743 (2015)[DOI]
- Borrelli O, "Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease", Dig Liver Dis, 36, pp.342~347 (2004)[DOI]
- Mamula P, "Inflammatory bowel disease in children 5 years of age and younger", Am J Gastroenterol, 97, pp.2005~2010 (2002)[DOI]
- Walters TD, "Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease", Gastroenterology, 146, pp.383~391 (2014)[DOI]
- Crombe V, "Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study", Inflamm Bowel Dis, 17, pp.2144~2152 (2011)[DOI]
- Church PC, "Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease", Inflamm Bowel Dis, 20, pp.1177~1186 (2014)[DOI]
- Hyams J, "Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension", Curr Med Res Opin, 27, pp.651~662 (2011)[DOI]
- Cameron FL, "Disease status and pubertal stage predict improved growth in antitumor necrosis factor therapy for pediatric inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 64, pp.47~55 (2017)[DOI]
- Levine A, "ESPGHAN revised Porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents", J Pediatr Gastroenterol Nutr, 58, pp.795~806 (2014)
- Hyams J, "Evaluation of the pediatric Crohn disease activity index: a prospective multicenter experience", J Pediatr Gastroenterol Nutr, 41, pp.416~421 (2005)[DOI]
- Levine A, "Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification", Inflamm Bowel Dis, 17, pp.1314~1321 (2011)[DOI]
- Lee MN, "Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine", Inflamm Bowel Dis, 21, pp.1054~1062 (2015)[DOI]
- Kang B, "Mucosal healing in paediatric patients with moderate-to-severe Luminal Crohn's disease under combined immunosuppression: escalation versus early treatment", J Crohns Colitis, 10, pp.1279~1286 (2016)[DOI]
- "2007 Korean Children and Adolescents Growth Standard (commentary for the development of 2007 growth chart)" (2007)[URL]
- Griffiths AM, "Growth and clinical course of children with Crohn's disease", Gut, 34, pp.939~943 (1993)[DOI]
- Motil KJ, "Growth failure in children with inflammatory bowel disease: a prospective study", Gastroenterology, 105, pp.681~691 (1993)[DOI]
- Ballinger A, "Fundamental mechanisms of growth failure in inflammatory bowel disease", Horm Res, 58(Suppl 1), pp.7~10 (2002)
- Ballinger AB, "Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis", Gut, 46, pp.694~700 (2000)
- Kirschner BS, "Reversal of growth retardation in Crohn's disease with therapy emphasizing oral nutritional restitution", Gastroenterology, 80, pp.10~15 (1981)
- Ungar B, "The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab", Gut, 63, pp.1258~1264 (2014)[DOI]
- Cucchiara S, "Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies?", J Pediatr Gastroenterol Nutr, 48, pp.257~267 (2009)[DOI]
- Kotlyar DS, "A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease", Clin Gastroenterol Hepatol, 9, pp.36~41 (2011)[DOI]
- Feagan BG, "Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease", Gastroenterology, 146, pp.681~688 (2014)[DOI]
- Cozijnsen MA, "Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease", Inflamm Bowel Dis, 21, pp.951~961 (2015)[DOI]
- Ballinger AB, "Delayed puberty associated with inflammatory bowel disease", Pediatr Res, 53, pp.205~210 (2003)[DOI]
- 천지영, "Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients", Pediatric Gastroenterology, Hepatology & Nutrition, 16(3), pp.171~177 (2013), 대한소아소화기영양학회